Translational Haematology
Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy
Milestones
1. Valentin Garcia Gutierrez. PI21//00877. Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies. (Carlos III Health Institute).
2. Javier Lopez Jimenez. Collaborating Investigator, H2020 European project RESILIENCE: REmote iSchemic conditioning in Lymphoma Patients REceiving ANthraCyclinEs. RESILIENCE randomized clinical trial. Carlos III National Center for Cardiovascular Research (CNIC), Spain. European Commission (Grant Agreement-945118-RESILIENCE)
3. Alejandro Luna. FEHH-Gilead Scholarship for Cellular Therapy Research Training at an International Center "Intrinsic tumor resistance mechanisms in CAR-T therapy for aggressive lymphomas" by Dr A Luna
4. CAR-T Therapy: Designation of the CAR-T center for the use of advanced therapies against hematological tumors in the adult population by the National Network of Advanced Therapies/Participation (Collaborating Researchers) PI22 CARTD-BG-01: Phase I trial, pilot, open , multicenter, non-randomized study to evaluate the safety and efficacy of ARI-0003 (CART19/269) cells in patients with relapsed/refractory aggressive B lymphoma
5. Valentin Garcia Gutierrez. Appointed President of the Spanish Chronic Myeloid Leukemia Group